{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.58","value":"24.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"description":"Duration in days in the study to the first minimum adapted ACR Pediatric 70 criteria and a normal (\\<10mg/L) C-Reactive Protein","dispersionType":"Standard Deviation","groups":[{"description":"In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or Placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a \\>0.2 mg/kg and ≤ 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤ 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.","id":"OG000","title":"Canakinumab"}],"paramType":"MEAN","populationDescription":"Participants from the Full Analysis Set Part I with ACR 70 and a Normal CRP.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 32","title":"Part I: Time to First Minimum American College of Rheumatology (ACR70) and Normal C-Reactive Protein","type":"SECONDARY","unitOfMeasure":"Days"}